The Pathophysiology of Parkinson's Disease:
Dopamine, Alpha-Synuclein, and Neuroinflammation

1. Dopamine and the Nigrostriatal Pathway

To understand Parkinson's disease pathogenesis, one must first appreciate the functional anatomy of the nigrostriatal dopaminergic system. Dopaminergic neurons originating in the substantia nigra pars compacta (SNpc) project via the nigrostriatal tract to the striatum (caudate nucleus and putamen), where dopamine release modulates the activity of the direct and indirect basal ganglia pathways.

The net effect of intact nigrostriatal dopamine transmission is facilitation of voluntary movement and suppression of unwanted motor activity. Progressive dopaminergic denervation disrupts this balance, producing the characteristic motor triad of Parkinson's disease. Critically, motor symptoms become clinically evident only after approximately 60–80% of nigral dopamine neurons have been lost — reflecting the considerable reserve capacity of the nigrostriatal system.

2. Alpha-Synuclein Aggregation and Lewy Body Formation

The molecular hallmark of Parkinson's disease is the aberrant misfolding and aggregation of alpha-synuclein (α-syn), a presynaptic protein normally involved in synaptic vesicle trafficking and neurotransmitter release. Under pathological conditions — influenced by genetic factors, oxidative stress, mitochondrial dysfunction, and environmental exposures — monomeric α-syn undergoes conformational change, forming oligomeric species and ultimately insoluble fibrillar aggregates.

These aggregates accumulate intraneuronally as Lewy bodies (eosinophilic cytoplasmic inclusions with a dense core and pale halo) and Lewy neurites. Proposed mechanisms of α-syn–mediated neurotoxicity include impairment of the ubiquitin-proteasome system, disruption of mitochondrial function, induction of endoplasmic reticulum stress, and direct membrane permeabilization by oligomeric species.

3. Neuroinflammation: Amplifier of Neurodegeneration

An increasingly recognized contributor to Parkinson's disease progression is neuroinflammation — specifically, the sustained activation of microglia (the resident immune cells of the CNS). In the healthy brain, microglia perform essential surveillance and neuroprotective functions. However, in the context of α-syn pathology, microglia adopt a pro-inflammatory (M1-like) activation state.

Activated microglia release pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reactive oxygen species, and nitric oxide, creating a hostile microenvironment that accelerates dopaminergic neuronal death. Post-mortem studies of Parkinson's disease brains demonstrate abundant activated microglia in the substantia nigra, and PET imaging using microglial activation tracers shows elevated neuroinflammation correlating with disease severity.

Critically, this neuroinflammatory response can become self-perpetuating: dying neurons release damage-associated molecular patterns (DAMPs), which further activate microglia in a feedforward loop. This mechanism provides a rationale for anti-neuroinflammatory therapeutic strategies, including nutritional interventions targeting the NF-κB and 5-LOX inflammatory pathways.

4. Etiology: A Multifactorial Disease

Parkinson's disease is etiologically heterogeneous. No single cause accounts for the majority of cases:

• Genetic factors: Pathogenic mutations in SNCA (α-synuclein), LRRK2, PRKN, PINK1, DJ-1, and GBA account for approximately 5–10% of cases. GBA mutations, encoding glucocerebrosidase, represent the most common genetic risk factor for sporadic Parkinson's disease, present in up to 10–15% of cases in some populations.
• Environmental exposures: Epidemiological data link chronic exposure to pesticides (rotenone, paraquat), herbicides, and heavy metals with increased Parkinson's disease risk, consistent with their known capacity to impair mitochondrial complex I function and induce oxidative stress.
• Oxidative stress: Dopamine metabolism itself generates reactive oxygen species through monoamine oxidase-mediated catabolism and auto-oxidation, rendering dopaminergic neurons intrinsically vulnerable to oxidative damage.
• The gut-brain axis: Compelling evidence supports a "gut-first" model in which enteric α-syn pathology propagates retrogradely to the brainstem via the vagus nerve — consistent with early gastrointestinal symptoms and the neuropathological staging observations of Braak et al.

5. Implications for Management

Understanding the molecular pathogenesis of Parkinson's disease informs a rational approach to management. While disease-modifying therapies targeting α-syn aggregation (immunotherapies, aggregation inhibitors) remain in clinical development, current evidence supports lifestyle interventions addressing modifiable pathogenic mechanisms: regular aerobic exercise promotes BDNF expression and reduces neuroinflammatory markers; antioxidant-rich nutrition addresses the oxidative vulnerability of dopaminergic neurons; and gut microbiome optimization may modulate the enteric environment implicated in disease initiation.